Bristol-Myers Squibb Company

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Consensus

Hold

Average target

$53.25

Implied upside

—

Analysts

17

Why Is BMY Up Today?

Bristol-Myers Squibb gained 1.78% today, supported by positive momentum from Q3 earnings results that included raised guidance and encouraging pipeline progress. However, the modest rally reflects lingering concerns about long-term patent cliff headwinds that continue to weigh on analyst sentiment despite near-term operational improvements.

Bottom line: BMY's 1.78% gain reflects justified optimism around Q3 execution and pipeline progress, but the stock remains constrained by fundamental patent cliff concerns that justify Morgan Stanley's Underweight stance. Investors should monitor Phase 3 readouts for newer programs like Pumitamig and watch for additional M&A or partnerships that could reshape the long-term revenue trajectory—these catalysts will ultimately determine whether BMY can trade beyond the $40 price target.